CareDx, Inc., The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025.
Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation and Cardiovascular Medicine, and has served as Section Chief of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support at Stanford University since 2017.
Health Technology Insights: ModMed Appoints Dr. Tomer Lancewicki to Lead AI Healthcare
Internationally recognized for his leadership and innovation in transplantation, Dr. Teuteberg has held prominent roles in the American Society of Transplantation (AST) and the International Society for Heart and Lung Transplantation (ISHLT), including serving as President of ISHLT and chairing multiple key committees and task forces. He has also served as principal investigator for the Surveillance HeartCare Outcomes Registry (SHORE) study, advancing the science of noninvasive rejection surveillance and outcomes in heart transplantation. Dr. Teuteberg’s contributions to multicenter clinical trials and guideline committees have helped shape the practice of heart transplantation worldwide.
Health Technology Insights: Rune Labs Appoints Digital Health Leader Adam Pellegrini to Board of Directors
“I am honored to join CareDx at such a pivotal time for the field of transplantation,” said Dr. Teuteberg. “Through my research, particularly as principal investigator of the SHORE study, I have witnessed the transformative impact of data-driven innovation on the patient experience and their outcomes. I look forward to helping CareDx drive the next generation of innovative solutions for transplant patients and the clinicians who care for them.”
“Dr. Teuteberg’s deep clinical expertise and leadership in transplant medicine are a tremendous fit for CareDx,” said John Hanna, President and Chief Executive Officer of CareDx. “His commitment to advancing patient care and his track record of clinical innovation will be invaluable as we continue to deliver on our mission to create life-changing solutions that enable transplant patients to thrive.”
Dr. Teuteberg will lead CareDx’s Medical Affairs activities globally, including its Medical Directors, Medical Science Liaisons, and clinical research operations, to further advance the company’s leadership and impact in the field of transplantation.
Health Technology Insights: Medix and Medix Technology Join Workday Partner Program to Provide HCM and Financial Solutions for Healthcare Clients
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
